Table 1 Characteristics of patients with active ocular toxoplasmosis
Patient no., age, gender, study eye | Symptom onseta | Lesion location (zone) | Lesion size (DD) | BCVA at baseline | BCVA at follow-up | IgM | IgG | Clinical findings |
|---|---|---|---|---|---|---|---|---|
1, 29 years, F, OD | 20 days | 1 | 2–3 | Hand motion | 20/125 | NR | R | ACC 3+, IRH, VC 2+, IRL |
2, 25 years, M, OS | 15 days | 2 | 1 | 20/20 | 20/20 | NR | R | ACC1+, RNV, VC1+ |
3, 22 years, M, OS | 1 day | 1 | < 1 | 20/60-2 | 20/25-1 | NR | R | ACC 3+, KP, VC 1+, IRL, CNVM |
4, 29 years, F, OD | 15 days | 1 | < 1 | 20/160 | 20/120-1 | R | R | ACC 3+, VC3+, IRL |
5, 20 years, M, OD | 4 days | 1 | < 1 | 20/25-2 | 20/20 | NR | R | VC 2+ |
6, 31 years, F, OS | 20 days | 1 | < 1 | 20/32 | 20/20 | NR | R | ACC 1+, VC 2+ |
7, 20 years, F, OD | 5 days | 1 | 1–2 | 20/125 | 20/40 | NR | R | ACC 3+, IRH, VC 1+ |
8, 15 years, F, OD | 10 days | 1 | 1–2 | 20/32-2 | 20/20 | NR | R | ACC 1+, VC 1+ |
9, 40 years, M, OD | 21 days | 1 | 2–3 | 20/500 | 20/334 | NR | R | ACC 3+, KP, VC 3+ |
10, 56 years, F, OS | 6 days | 1 | < 1 | Hand motion | 20/30 | NR | R | ACC 3+, KP, VC 2+ |
11, 41 years, F, OD | 15 days | 1 | 1–2 | 20/160 | 20/125 | R | R | ACC 2+, VC 2+ |
12, 39 years, F, OD | 5 days | 1 | 1–2 | 20/100 | 20/32 | NR | R | ACC 3+, VC1+ |
13, 28 years, M, OS | 6 days | 1 | 3 | 20/334 | 20/40 | NR | R | ACC 3+, KP, VC 1+ |
14, 59 years, F, OS | 15 days | 1 | > 6 DP | 20/125 | 20/40 | NR | R | ACC 3+, VC 2+ |
15, 32 years, M, OD | 5 days | 1 | 1–2 | CF 1 m | 20/100 | R | R | ACC 2+, VC 1+ |